News Headlines

Display #
Title
Towards a safe and scalable cell therapy for type 1 diabetes by simplifying beta cell differentiation
Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream
Takeda Splits Off a Range of Businesses to Focus on R&D
EMA clears Actelion’s Uptravi after safety review
FDA rejects application for diabetes drug labels
FDA Approves New Indications for Harvoni. Sovaldi
Trump nominee to lead FDA questioned on ties to pharma industry
Experts want special clinics to prescribe ketamine as antidepressant
FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Elizabeth Holmes Now Owes Theranos $25 Million
A one-two punch hits pancreatic cancer where it hurts
Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
Mallinckrodt resigns membership from PhRMA
House panel to consider tweaks to healthcare bill before recess
FDA allows marketing of DTC tests for diseases
Consulting at McCann Health Appoints Two Execs
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
New drug delivery system shows promise for fighting solid tumors
Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer
Kite Highlights Publication on Breakthrough in Generating Fully Functioning T Cells from Hematopoietic Precursor Cells by Leading Researchers at the University of California, Los Angeles (UCLA)
Struggling Aviragen Slashes 25% of Workforce, Considers Strategic Options
Ryan dampens hopes for quick revival of U.S. healthcare overhaul
GSK recalling nearly 600,000 asthma inhalers in U.S.
Stem cells plus scaffold may spur repair of torn tendons
Deep learning algorithm could boost drug development
Unfavorable Ruling Forces Acorda to Pink Slip 20% of Jobs
First collaborative definition of patient centricity
Unilife Slashes Workforce and May Not Have Enough Cash to Survive Beyond This Week
Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO
Corbus outlines U.S. approval path for lead drug